Covid-19 Long Immunité IMagerie (CLIIM)
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Jul 29, 2024
Trial Information
Current as of September 13, 2025
Recruiting
Keywords
ClinConnect Summary
The Covid-19 Long Immunité IMagerie (CLIIM) trial is a research study focused on understanding "long COVID," a condition where some people experience ongoing symptoms long after recovering from the initial COVID-19 infection. The goal of this study is to identify specific biological markers that could help doctors diagnose long COVID more easily and track how it changes over time. Researchers will start by including 120 participants, dividing them into two groups: one group with long COVID symptoms and another group without. After this initial phase, they will validate their findings by including an additional 80 patients.
To participate in the study, people must meet certain criteria. For those with long COVID (CL+), they need to have symptoms that align with guidelines from the World Health Organization. For control participants (CL-), they should have had COVID-19 but no lingering symptoms for more than three months. Participants can expect to be part of a study that aims to improve understanding and management of long COVID, but they should also be aware that the study is not yet recruiting. Remember, this research is crucial for finding better ways to help those affected by long COVID.
Gender
ALL
Eligibility criteria
- • FOR CL+ PATIENTS
- Inclusion Criteria:
- • Case definition in line with WHO Delphi process
- Exclusion Criteria:
- • History of chronic fatigue syndrome diagnosed before or after Covid.
- • History of progressive psychiatric pathology.
- • History of acute Covid requiring admission to intensive care and mechanical ventilation.
- • No social security affiliation.
- • FOR CONTROL (CL-)
- Inclusion Criteria:
- • History of acute COVID-19, mild, moderate or severe (episode at least 3 months at the time of inclusion).
- • Absence of persistent symptoms more than 3 months after first Covid symptoms (or mild not affecting daily activities).
- Exclusion Criteria:
- • History of progressive psychiatric pathology.
- • History of acute Covid requiring admission to intensive care and mechanical ventilation.
- • No social security affiliation.
- • Pregnant or breast-feeding.
About Centre Hospitalier Universitaire De Nice
The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, France
Nice, Alpes Maritimes, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported